Testing FCN-159 for children with LCH that returned
Treatments studied
Part of Blood & lymphatic, Lungs & breathing clinical trials.
This trial tests a study drug, FCN-159, for children with a rare blood/immune disease called Langerhans cell histiocytosis (LCH) that has not responded to standard treatment or has come back. The goal is to see if this drug can shrink the LCH lesions and help the child feel better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 2 to 16 years
- Diagnosis of Langerhans cell histiocytosis (LCH) confirmed by a central lab
- Must have received at least one prior treatment for LCH (like vinblastine and steroids) or had severe side effects from that treatment
- LCH must be refractory (not responding) or relapsed (came back after treatment)
- Must have LCH lesions that can be measured on a PET scan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, low-dose cytarabine and thalidomide, for adults with Langerhans cell histiocytosis (LCH) that has not been treated before with systemic therapy. The goal is to see if this treatment is safe and effective for people with LCH in multiple body areas or multiple spots in one system.
This Phase 3 trial tests a treatment plan that includes cytarabine for children newly diagnosed with LCH (a rare condition where abnormal immune-related cells form lesions). It may help control the disease while comparing outcomes with a cytarabine-based protocol.
This trial tests a new targeted drug called luvometinib, either alone or with a standard chemotherapy drug (cytarabine), for people with Langerhans cell histiocytosis. The goal is to see if adjusting the treatment based on your response can help control the disease.
This trial tests a targeted drug called trametinib (a MEK inhibitor) for people with Langerhans cell histiocytosis (LCH) that is newly diagnosed, relapsed, or hasn't responded to other treatments. It aims to see if trametinib can better control the disease with fewer side effects.
This phase 3 study compares two treatment plans for Langerhans cell histiocytosis (LCH): vinblastine plus prednisone versus cytarabine alone. It aims to find which approach works better and is safer for children and young adults with LCH that needs medicines.
This trial tests whether a new oral drug called FCN-159 works better than standard chemotherapy for children and teens with a slow-growing brain tumor (low-grade glioma) that has a specific change in the BRAF gene. The goal is to see if FCN-159 can shrink the tumor or stop it from growing.
Hear when a new Langerhans Cell Histiocytosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.